Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

American journal of hematology - 1 Feb 2015

Tefferi Ayalew, Barbui Tiziano

Abstract excerpt

DISEASE OVERVIEW: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms, respectively characterized by erythrocytosis and thrombocytosis. Other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation. DIAGNOSIS: PV is defined by a JAK2 mutation, whose absence, combined with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aspirin
Share to Calreticulin
Share to Hydroxyurea

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Receptors, Thrombopoietin

Share to Thrombocythemia, Essential

Share to Thrombocytosis

Source

Identifiers

PMID: 25611051
DOI: 10.1002/ajh.23895

Genes

JAK2
CALR
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.PMID 25611051Read ↗

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.Semantic proximity Read ↗

Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.Semantic proximity Read ↗

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Thrombosis-Driven Disease Progression in JAK2-Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk-Based Management.Semantic proximity Read ↗

Polycythemia Vera: Rapid Evidence Review.Semantic proximity Read ↗

Austrian recommendations for the management of essential thrombocythemia.Semantic proximity Read ↗

The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort.Semantic proximity Read ↗

Polycythemia vera.Semantic proximity Read ↗

The new WHO classification for essential thrombocythemia calls for revision of available evidences.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.